JPMorgan Chase & Co. 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-06 10:52 am Sale |
2025-02-28 | 13G | Revance Therapeutics, Inc. RVNC |
J P MORGAN CHASE & CO JPM |
0 0.000% |
-5,686,631 (Position Closed) |
Filing |
| 2025-02-11 12:16 pm Purchase |
2024-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
J P MORGAN CHASE & CO JPM |
5,686,631 5.400% |
2,917,940 (+105.39%) |
Filing |
| 2024-04-09 1:17 pm Sale |
2024-03-29 | 13G | Revance Therapeutics, Inc. RVNC |
J P MORGAN CHASE & CO JPM |
2,768,691 2.600% |
-1,986,080 (-41.77%) |
Filing |
| 2024-01-25 11:11 am Unchanged |
2023-12-29 | 13G | Revance Therapeutics, Inc. RVNC |
J P MORGAN CHASE & CO JPM |
4,754,771 5.400% |
0 (Unchanged) |
Filing |
| 2024-01-25 11:10 am Sale |
2023-12-29 | 13G | Revance Therapeutics, Inc. RVNC |
J P MORGAN CHASE & CO JPM |
4,754,771 5.400% |
-228,178 (-4.58%) |
Filing |
| 2023-01-27 12:22 pm Sale |
2022-12-30 | 13G | Revance Therapeutics, Inc. RVNC |
J P MORGAN CHASE & CO JPM |
4,982,949 6.000% |
-1,811,274 (-26.66%) |
Filing |
| 2022-01-18 12:59 pm Purchase |
2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
J P MORGAN CHASE & CO JPM |
6,794,223 9.400% |
2,727,181 (+67.06%) |
Filing |
| 2021-01-29 09:25 am Purchase |
2020-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
J P MORGAN CHASE & CO JPM |
4,067,042 6.100% |
38,545 (+0.96%) |
Filing |